JP2019043879A - Intestinal microbiota balance improver - Google Patents

Abstract

To provide a novel intestinal microbiota balance improver.SOLUTION: An intestinal microbiota balance improver contains proteoglycan as an active ingredient. The intestinal microbiota balance improver can be put into various forms of drugs and directly taken or administered as pharmaceuticals or health foods; or can be eaten or drunk by blending into various foods and drinks.SELECTED DRAWING: Figure 1

Description

  The present invention relates to a novel intestinal microbiota balance improving agent.

  In the intestines of humans, enteric microbiota (enteric microbes) while maintaining balance among approximately 1,000 types of enteric bacteria such as useful bacteria (good bacteria), harmful bacteria (bad bacteria) and opportunistic bacteria. It is known that it forms flora, intestinal bacterial flora) and regulates systemic immunity. If the balance is broken for some reason, the immune regulation is disturbed and negatively affects the living body, so the balance is disrupted when the intestinal microbiota balance is disturbed. Although various ingredients have been proposed (for example, Patent Document 1), better ingredients are needed.

JP, 2014-70058, A

  Then, an object of the present invention is to provide a novel agent for improving balance of intestinal microbiota.

  As a result of intensive studies conducted by the present inventors in view of the above-described points, proteoglycan known as a main component of the cartilage of an animal together with collagen and hyaluronic acid has been found to cause intestinal microbiota caused by intake of a high lipid diet. It has been found to improve the imbalance of Biota.

  The balance improving agent for intestinal microbiota of the present invention made based on the above findings contains proteoglycan as an active ingredient as described in claim 1.

  According to the present invention, it is possible to provide a novel intestinal microbiota balance improving agent containing proteoglycan as an active ingredient.

In Example 1, it is a graph which shows that proteoglycan improves the collapse of the balance of intestinal microbiota caused by the intake of a high lipid diet.

  The balance improving agent for intestinal microbiota of the present invention contains proteoglycan as an active ingredient.

  The proteoglycan used as an active ingredient in the present invention includes, for example, those purified using cartilage such as salmon, shark, cow and whale as a raw material. As a purification method of proteoglycan, a method using acetic acid described in JP-A-2002-69097 can be exemplified. In this method, for example, crude proteoglycan is eluted from minced salmon nasal cartilage using acetic acid as an elution solvent, the resulting eluate is filtered and then centrifuged, and sodium chloride saturated ethanol is added to the supernatant. The reaction is carried out by dissolving in acetic acid a semisolid precipitate containing crude proteoglycan obtained by centrifuging, followed by dialysis, and according to this method, for example, a molecular weight of about 100 to 400 kDa from salmon cartilage of salmon Proteoglycan can be obtained.

  The proteoglycan used as an active ingredient in the present invention can be taken and taken as medicines and health foods by formulating in various formulation forms, and in addition, it can be contained in various food and drink products , Intestinal microbiota exerts balance improvement action. The amount applied varies depending on the age and weight of the user, the degree of symptoms, the form of application and the like, but is not particularly limited.

  Hereinafter, the present invention will be described in detail by way of examples, but the present invention is not construed as being limited to the following description.

Example 1:
The effect of proteoglycans on the breakdown of intestinal microbiota balance caused by the intake of a high lipid diet was examined by the following method. The proteoglycan used was a commercial product derived from salmon nasal cartilage (manufactured by Kakuhiro Co., Ltd.).

(experimental method)
Four-week-old female ICR mice were divided into the following four groups (one group: 5 to 6).
・ Fat component 5.6% regular diet (ND) feeding group ・ fat component 60% high fat diet (HFD) feeding group ・ HFD feeding + proteoglycan drinking administration group ・ proteoglycan combination HFD feeding group Proteoglycan water is individual mouse in advance Proteoglycan was dissolved in distilled water so that each mouse could consume 1 mg of proteoglycan per day. The proteoglycan-containing HFD was prepared by mixing the proteoglycan in the HFD so that the individual mice ingested 1 mg of proteoglycan per day, while examining the average daily intake of HFD of each mouse in advance. Donation to mice was started at 4 weeks of age, fed for 12 weeks, euthanized, cecal contents collected, and QIAamp DNA stool Mini kit (Qiagen) was used to extract enteric bacterial DNA The proportions of major enteric bacteria ( Eubacterium , Bacteroides , Clostridium , Lactobacillus , Bifidobacterium ) were analyzed by Real-time PCR (For details of procedures including the primers used, see Takagi Matsuki. Human intestinal flora-forming bacteria. Establishment of quantitative PCR detection method and analysis of genus / species distribution. See Japanese Bacteriological Journal. 2007, 62: 255-261.

(Experimental result)
It is shown in FIG. As apparent from FIG. 1, the ratio of Bifidobacterium to Clostridium in the HFD-fed group (H) is significantly higher than that in the ND-fed group (N), but with the HFD-fed + proteoglycan drinking dose group (HdP) Their ratio in the proteoglycan-blended HFD-fed group (HfP) was significantly lower than their ratio in the HFD-fed group (H), and approximately the same as their ratio in the ND-fed group (N). From the above results, it was found that proteoglycans improve the balance of intestinal microbiota by increasing the ratio of Bifidobacterium and Clostridium caused by the intake of a lipid- rich diet. Proteoglycans are known to have anti-obesity and anti-diabetic effects (Japanese Patent Laid-Open No. 2010-126461. Also in this experiment, the weight gain suppressive action and the blood glucose level suppressive action of proteoglycan have been confirmed), In addition, obese and diabetic patients are known to have a high ratio of Clostridium in the intestine (Karlsson FH et al. Nature 2013, 498: 99-103, etc.). Considering the present experimental results in conjunction with these findings, it is possible to consider the balance-improving action of proteoglycan in intestinal microbiota as one of the mechanisms of the anti-obesity action and anti-diabetic action of proteoglycan.

Formulation Example 1: Tablet A tablet for improving the imbalance of intestinal microbiota comprising the following component composition was produced by a method known per se.
Proteoglycan 1
Lactose 80
Magnesium stearate 19 (unit: wt%)

Formulation Example 2 Biscuit A biscuit was manufactured by a method known per se to improve the balance of intestinal microbiota having the following component composition.
Proteoglycan 1
Flour flour 32
Whole eggs 16
Butter 16
Sugar 24
Water 10
Baking powder 1 (% by weight)

  The present invention has industrial applicability in that it can provide a novel intestinal microbiota balance improving agent.

Claims (1)

  An agent for improving balance of intestinal microbiota comprising proteoglycan as an active ingredient.